In honor of Rare Disease Day, the Celtics are teaming with Takeda Pharmaceuticals to raise awareness and support for the rare disease community.

Protagonist Therapeutics, Inc. ("Protagonist") and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough ...

During his tenure, he has helped drive key transactions resulting in over $7 billion in upfront and milestone capital from pharmaceutical partners, including the TYK2 sale to Takeda in 2022.

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

Takeda’s (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit and chair of the Plasma Protein ...

CBO Abbas Kazimi will replace longtime CEO Jeb Keiper as part of a planned leadership transition at the unorthodox drug startup.

But sharing a smooch in a photo booth takes things to another level. "You get to go into like this tiny box together. It's very personal," said Andrew Wills, who was visiting San Francisco's ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other Japanese stocks. As the dangers of natural disasters increase and ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...